Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBIT: 2021-2025

Historic EBIT for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $41.4 million.

  • Krystal Biotech's EBIT rose 84.11% to $41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.2 million, marking a year-over-year increase of 475.37%. This contributed to the annual value of $65.7 million for FY2024, which is 159.87% up from last year.
  • Per Krystal Biotech's latest filing, its EBIT stood at $41.4 million for Q3 2025, which was up 5.26% from $39.3 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's EBIT peaked at $41.4 million during Q3 2025, and registered a low of -$50.2 million during Q1 2022.
  • Its 3-year average for EBIT is $6.6 million, with a median of $8.6 million in 2024.
  • As far as peak fluctuations go, Krystal Biotech's EBIT crashed by 249.91% in 2022, and later surged by 1,216.83% in 2024.
  • Krystal Biotech's EBIT (Quarterly) stood at -$21.9 million in 2021, then crashed by 58.95% to -$34.8 million in 2022, then skyrocketed by 109.02% to $3.1 million in 2023, then soared by 1,216.83% to $41.3 million in 2024, then spiked by 84.11% to $41.4 million in 2025.
  • Its EBIT stands at $41.4 million for Q3 2025, versus $39.3 million for Q2 2025 and $36.2 million for Q1 2025.